Clinical Trials in Naples, Campania
82 recruiting
Showing 1–20 of 66 trials
Recruiting
Phase 3
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Takeda171 enrolled112 locationsNCT06722235
Recruiting
Phase 3
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Crohn's DiseaseUlcerative Colitis
Takeda240 enrolled98 locationsNCT05442567
Recruiting
Phase 2
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Heart Failure
Bristol-Myers Squibb208 enrolled117 locationsNCT06122779
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled207 locationsNCT06422143
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled277 locationsNCT07063745
Recruiting
Phase 2
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Acute Lymphoblastic Leukemia
Pfizer100 enrolled76 locationsNCT05748171
Recruiting
Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Alzheimers Disease
Hoffmann-La Roche13,000 enrolled211 locationsNCT07177352
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Parkinson's Disease
Hoffmann-La Roche900 enrolled142 locationsNCT07174310
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled141 locationsNCT06157892
Recruiting
Phase 3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC904 enrolled105 locationsNCT07227402
Recruiting
Phase 3
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Uveal Melanoma
IDEAYA Biosciences520 enrolled94 locationsNCT07015190
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Hoffmann-La Roche450 enrolled226 locationsNCT06790693
Recruiting
Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting
Phase 3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche2,000 enrolled484 locationsNCT05878769
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb690 enrolled161 locationsNCT07221149
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
Hoffmann-La Roche600 enrolled362 locationsNCT06819878
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled216 locationsNCT06345729
Recruiting
Phase 3
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Crohn's Disease (CD)
Takeda120 enrolled96 locationsNCT04779320
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled288 locationsNCT06393374